Highlights: Retatrutide targets GLP-1, GIP, and glucagon to reduce appetite, regulate fat storage, and manage blood sugar A trial showed a higher dose of Retatrutide produced 20% more weight loss over 48 weeks Common side effects include diarrhea, nausea, and vomiting , with at least one death reported Trusted Source Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial Go to source)
GLP-1 drugs arent new, having been used to treat Type 2 diabetes since 2005
PCOS-specific nutrition guidance : We provide clear guidance on what to eat to maximize results and minimize side effects
Retatrutide extends this research framework by adding glucagon receptor activity to a GIP and GLP-1 receptor signaling profile
Were a few years in, but it usually takes about 20 years of patient data to fully understand the true risk of a drug
If unopened, the vial can remain effective until the expiration date indicated by the manufacturer, provided it is kept refrigerated